Gilead Sciences Appoints Dr. Merdad Parsey as Global Chief Medical Officer

Gilead Sciences Announces Appointment of Merdad Parsey, M.D., as Global Chief Medical Officer, Effective November 1

Dr. Parsey will lead the company’s global clinical development and medical affairs teams, becoming a member of the global senior management team and reporting directly to Daniel O’Day, Chairman of the Board and Chief Executive Officer of Gilead Sciences. Under the new organizational structure, Dr. William Lee, Executive Vice President and Head of Drug Research at Gilead Sciences, will also report to Mr. O’Day.

Dr. Parsey currently serves as Senior Vice President of Early Clinical Development at Genentech, a member of the Roche Group, overseeing departments including clinical development, quality, compliance, informatics, and clinical operations. His appointment will bring highly valuable clinical research experience and expertise to Gilead Sciences across a broad range of therapeutic areas, including inflammatory diseases, oncology, and infectious diseases.

Chairman of the Board and Chief Executive Officer of Gilead Sciences, Inc.

Daniel O’Day stated:

“

Merdad is a highly experienced and respected scientist, clinical research expert, and leader. I am delighted that he will be joining Gilead Sciences. As a leader, Merdad has earned an outstanding reputation throughout his career across academia, industry, and the medical community. Gilead Sciences is rapidly expanding its product pipeline and clinical development portfolio through internal efforts and external collaborations. I am confident that Merdad’s exceptional capabilities and expertise will greatly benefit the company in the field of research and development.

”

Prior to joining Genentech, Dr. Parsey served as President and Chief Executive Officer of 3-V Biosciences. He has also engaged in drug development at Sepracor, Regeneron, and Merck, and held the positions of Assistant Professor of Medicine and Director of Critical Care Medicine at New York University School of Medicine. Dr. Parsey earned his M.D. from the University of Maryland, Baltimore, completed his internal medicine residency at Stanford University, and pursued fellowship training in pulmonary and critical care medicine at the University of Colorado.

Dr. Parsey stated:

“

Throughout my career, I have repeatedly participated in and formulated clinical development strategies and project plans for pharmaceuticals. I am thrilled to bring my experience to Gilead Sciences, a company I have long admired. I look forward to collaborating with the company’s talented team to advance clinical development projects, build a robust product pipeline, explore innovative disease therapies, and strive to help more people around the world who are in need of transformative medical support.

”